Common use

Olumiant is a prescription medication widely used to treat moderate to severe rheumatoid arthritis in adults who have not responded adequately to one or more disease-modifying antirheumatic drugs (DMARDs). As a trusted JAK inhibitor, Olumiant has also earned FDA approval for treating severe alopecia areata and atopic dermatitis, making it a versatile immune modulator for multiple autoimmune conditions. The active ingredient, baricitinib, belongs to the Janus kinase inhibitor class and works by selectively blocking JAK1 and JAK2 enzymes responsible for triggering inflammatory pathways. By reducing overactive immune signaling, Olumiant helps relieve debilitating symptoms like chronic joint pain, swelling, morning stiffness, and skin inflammation, significantly improving quality of life for patients living with autoimmune disorders. If you want to buy Olumiant online, DutyPills offers genuine baricitinib at competitive prices with fast, discreet delivery.

Dosage and direction

The standard recommended dosage of Olumiant is 2 mg taken once daily by mouth, with or without food. Your healthcare provider may prescribe a lower 1 mg dose for patients with kidney impairment or those taking certain concomitant medications, or a higher 4 mg dose depending on disease severity and individual tolerance. The tablet should be swallowed whole with a full glass of water and taken at the same time each day to maintain consistent blood levels of baricitinib. Dosage adjustments may be necessary in patients with moderate to severe renal impairment or hepatic dysfunction. Do not crush, chew, or split the tablet. Your doctor will determine the optimal dose based on your specific condition, response to treatment, and any concurrent medications you may be taking.

Precautions

Before starting Olumiant, inform your doctor about your complete medical history, particularly if you have a history of recurrent infections, active or latent tuberculosis, blood clots (deep vein thrombosis or pulmonary embolism), liver or kidney disease, diverticulitis, or any history of cancer. As a potent immune modulator, baricitinib suppresses certain immune functions, which may increase susceptibility to serious infections including herpes zoster, upper respiratory infections, and opportunistic pathogens. Regular monitoring through comprehensive blood tests is essential to track liver enzymes, lipid panels, complete blood counts, and lymphocyte levels throughout treatment. Patients should receive all recommended vaccinations before beginning therapy and must avoid live vaccines during treatment. Women of childbearing age should use effective contraception, as the effects of this JAK inhibitor on fetal development have not been fully established.

Contraindications

Olumiant is contraindicated in patients with known hypersensitivity to baricitinib or any inactive ingredients in the formulation. It must not be used by patients with severe active infections such as active tuberculosis, systemic fungal infections, or sepsis. The medication is not recommended during pregnancy or breastfeeding unless the potential benefit clearly justifies the potential risk to the fetus or infant. Patients with absolute lymphocyte counts below 200 cells/mm3, absolute neutrophil counts below 500 cells/mm3, or hemoglobin levels below 8 g/dL should not initiate therapy. Caution is strongly advised in patients with a personal or family history of blood clots, cardiovascular events, or malignancies, as clinical studies have shown potential increased risks in these areas.

Possible side effect

Common side effects of Olumiant include upper respiratory tract infections, nausea, headache, herpes simplex reactivation, and elevated cholesterol levels. Some patients may experience changes in liver enzyme values, reduced white blood cell or platelet counts, urinary tract infections, or acne. Gastrointestinal symptoms such as stomach pain or diarrhea have also been reported. Rare but serious side effects associated with this JAK inhibitor include venous thromboembolism (blood clots in legs or lungs), serious or life-threatening infections, gastrointestinal perforations, and an increased risk of certain cancers including lymphoma. Seek immediate medical attention if you experience sudden chest pain, shortness of breath, leg swelling, persistent fever, unusual bruising or bleeding, or signs of an allergic reaction such as hives, facial swelling, or difficulty breathing.

Drug interaction

Olumiant may interact with several classes of medications that affect immune function. Concurrent use with biologic DMARDs (such as adalimumab, etanercept, or tocilizumab), potent immunosuppressants like azathioprine or cyclosporine, or other JAK inhibitors is not recommended due to the risk of additive immunosuppression. Strong OAT3 inhibitors such as probenecid may increase baricitinib plasma levels, potentially requiring dose reduction. Inform your healthcare provider about all prescription and over-the-counter medications, vitamins, and supplements you are taking, including herbal products. Drug interactions may necessitate dosage changes, additional monitoring, or alternative treatment strategies to ensure your safety while using this autoimmune therapy.

Missed dose

If you miss a dose of Olumiant, take it as soon as you remember on the same day. If it is already close to the time for your next scheduled dose, skip the missed dose entirely and continue with your regular dosing schedule. Never take two doses at once or extra doses to make up for a missed one, as this may increase the risk of side effects. Consistency in taking baricitinib at the same time each day is important for maintaining stable drug levels and optimal treatment effectiveness for your autoimmune condition.

Overdose

In case of an accidental overdose of Olumiant, seek immediate medical attention or contact your local poison control center. Symptoms of baricitinib overdose may include severe nausea, dizziness, headache, or increased susceptibility to infection due to excessive immune suppression. There is no specific antidote for baricitinib overdose; treatment will involve supportive medical care, symptom management, and careful monitoring of vital signs and laboratory values. Hemodialysis is not expected to significantly remove the drug from the body.

Storage

Store Olumiant tablets at controlled room temperature between 15–30°C (59–86°F), protected from moisture, excessive heat, and direct light. Keep the tablets in their original container with the lid tightly closed to maintain medication integrity. Do not transfer tablets to pill organizers exposed to humidity. Do not use Olumiant after the expiration date printed on the package. Keep this medication out of reach of children and pets at all times.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.